Macrophage Dysfunction in Tuberculosis–Diabetes Mellitus Comorbidity: A Scoping Review of Immune Dysregulation and Disease Progression
Open Access
- 2 May 2025
- journal article
- review article
- Published by MDPI AG in Diabetology
- Vol. 6 (5) , 35
Abstract
Background: Tuberculosis (TB) and diabetes mellitus (DM) comorbidity (TB-DM) presents a significant global health challenge, with diabetes increasing susceptibility to TB, worsening clinical outcomes, and impairing immune responses. Among these dysfunctions, macrophages—the primary immune cells responsible for pathogen recognition, phagocytosis, and bacterial clearance—exhibit profound alterations in TB-DM. However, the complex interplay between metabolic dysregulation, immune impairment, and macrophage dysfunction remains poorly defined. Objective: This scoping review systematically maps the literature on macrophage dysfunction in TB-DM, identifying key immunological impairments affecting phagocytosis, cytokine production, antigen presentation, macrophage polarisation, reactive oxygen species (ROS) and nitric oxide (NO) regulation, and chronic inflammation. Methods: A systematic search was conducted in PubMed, Web of Science, and Embase, covering studies from 2014 to 2024. Inclusion criteria focused on human studies investigating macrophage-specific mechanisms in TB-DM. Data extraction and synthesis were performed using Covidence, with findings grouped into key immunological themes. Results: A total of 44 studies were included, revealing significant impairments in macrophage function in TB-DM. Findings indicate reduced NO production, variable ROS dysregulation, altered M1/M2 polarisation, defective antigen presentation, and chronic inflammation. Elevated IL-10 and VEGF were associated with immune suppression and granuloma destabilisation, while eicosanoids (PGE2, LXA4) contributed to sustained inflammation. Conclusions: Macrophage dysfunction emerges as a central driver of immune failure in TB-DM, creating a self-perpetuating cycle of inflammation, immune exhaustion, and bacterial persistence. Understanding these mechanisms is essential for developing biomarker-driven diagnostics, host-directed therapies, targeted immunomodulation, and improving TB outcomes in diabetic populations. Future research should explore macrophage-targeted interventions to enhance immune function and mitigate TB-DM burden.Keywords
This publication has 72 references indexed in Scilit:
- Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspectiveExploration, 2024
- Hyperglycemia modulates M1/M2 macrophage polarization in chronic diabetic patients with pulmonary tuberculosis infectionImmunobiology, 2024
- Chronic hyperglycemia drives alterations in macrophage effector function in pulmonary tuberculosisEuropean Journal of Immunology, 2022
- Serum levels of novel anti-inflammatory cytokine Interleukin-38 in diabetes patients infected with latent tuberculosis (DM-LTB-3)Journal of Diabetes and its Complications, 2022
- Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated InflammationCell Metabolism, 2020
- Improved Mycobacterium tuberculosis clearance after the restoration of IFN‐γ+TNF‐α+CD4+T cells: Impact of PD‐1 inhibition in active tuberculosis patientsEuropean Journal of Immunology, 2020
- Patients with type 1 diabetes mellitus have impaired IL-1β production in response to Mycobacterium tuberculosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- Type 2 diabetes mellitus coincident with pulmonary or latent tuberculosis results in modulation of adipocytokinesCytokine, 2016
- Coincident diabetes mellitus modulates Th1‐, Th2‐, and Th17‐cell responses in latent tuberculosis in an IL‐10‐ and TGF‐β‐dependent mannerEuropean Journal of Immunology, 2015
- Diabetes and immunity to tuberculosisEuropean Journal of Immunology, 2014